Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma — Masatoshi Kudo (2024) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma
Shared by
Masatoshi Kudo
Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma
Editorial Material
2024
en
Authors
Masatoshi Kudo
Abstract
1 min read
NA
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2022
Performance evaluation of the Elecsys <scp>PIVKA‐II</scp> and Elecsys AFP assays for hepatocellular carcinoma diagnosis
Henry Lik‐Yuen Chan
,
Arndt Vogel
,
Thomas Berg
,
Enrico N. De Toni
,
Masatoshi Kudo
,
Jörg Trojan
,
Anja Eiblmaier
,
Hanns‐Georg Klein
,
Johannes Kolja Hegel
,
Ashish Sharma
,
Kairat Madin
,
Vinzent Rolny
,
Marcus‐Rene Lisy
,
Teerha Piratvisuth
Letter
2009
Testing Molecular Therapies in Hepatocellular Carcinoma: The Need for Randomized Phase II Trials
Josep M. Llovet
,
Jordi Bruix
Journal of Clinical Oncology
Editorial Material
2023
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
Masatoshi Kudo
Editorial Material
2022
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
Masatoshi Kudo
Editorial Material
2023
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Masatoshi Kudo
Discussion(0)
No comments yet. Be the first to comment.